Inmune Bio, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
INmune Bio entered a Master Services Agreement with Uniphar Durbin Ireland Limited on October 21, 2026, establishing a framework for international commercialization of Ebstrocel (its investigational cell therapy for RDEB). Initial focus is named-patient access in selected European and MENA markets. Concurrently, the company submitted its final pre-MAA package to UK MHRA on October 20, 2026, and accelerated its regulatory timeline: full MAA targeted for February 2027 (instead of rolling submission in late 2026), with potential UK approval in mid-2027—approximately six weeks earlier than previously planned. U.S. BLA submission planned for Q2 2027.
Why this rating
Ebstrocel is INmune Bio's lead asset; regulatory progress + international commercial infrastructure significantly advance path to first revenue. Material relative to $51M market cap.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.